NINJA: an inducible genetic model for creating neoantigens in vivo

Background:

It has become increasingly clear that the immune system plays a critical role in tumour evolution. Although current mouse models in the cancer field have greatly contributed to our understanding of cancer, the simplicity of these models, which allowed scientists to map the steps of tumour initiation through metastasis, are also a weakness, as the lack of neoantigens due to low mutational burden means modelling a tumour immune response is difficult ^1,2,3,4. In human cancer patients, neoantigens are generated by the DNA damage that drives and sustains tumours ⁵. Mouse models with inducible neoantigens have been generated, but central tolerance in the mice makes them suboptimal for studying the immune response. Methods utilizing viruses have been developed with some success, but prolonged T cell exposure led to an ineffective antitumour response⁶. In this preprint, the authors aim to produce a pre-clinical mouse model with an inducible neoantigen construct that escapes mouse immune tolerance, which is an ideal system for studying immunological tolerance in peripheral tissues and the immune response to cancer.

 

Key Findings:

The authors designed a novel genetically engineered mouse model (GEMM) with an inducible construct containing a neoantigen that is successfully hidden from the central and peripheral immune system until induced. This feat was accomplished with three levels of regulation (Figure 1a) including a regulatory element that must be induced by viral Cre-recombinase, followed by exposure of the mice to two additional molecules commonly used in the field to temporally control gene induction. Once all three elements are added to the system, exon 2 of the neoantigen is inverted and expressed. This complex system prevents leakiness of the neoantigen construct and allows for spatial and temporal control of the expression of the neoantigen and so the subsequent immune response to it.

 

The authors first aim to simply confirm expression of the neoantigen in vitro. They choose the highly transfectable human embryonic kidney cell lines 293T. They transfect the neoantigen module into this cell line and confirm it functions as expected. The authors next wanted to confirm the neoantigen they chose would stimulate the expected T cell response. GP33-specific CD8 T cells were activated and proliferated in the presence of the activated neoantigen module. This is critical as the authors aim to make a system that mimics the T cell response in the presence of a novel neoantigen in a tumour.

The authors then aimed to test for a T cell response in a transplantable system. This is an important next step as making a novel GEMM is quite labour intensive, so validating the system in a simpler in vivo model is critical. The KP lung cancer cell line was used to generate a knock-in cell line with the NINJA targeting construct (KP-C4). The KP-C4 cell line was transduced with an rtTA-encoding retrovirus and infected with a recombinant Cre-expressing adenoviral vector, which caused recombination and put the regulatory module in the poised state (KP-C4A3D6). When KP-C4A3D6 cells were infected with FLPo or treated with doxycycline and 4-hydroxytamoxifen, GFP and the neoantigen module were expressed.

Immunogenicity was tested using KP-C4A3D6 cells sorted for GFP (neoantigen expressing) compared to GFP negative KP-C4A3D6 (not expressing neoantigen). Cells were implanted intramuscularly and neoantigen-specific firefly-luciferase (fLuc)-expressing CD8 T cells were tracked in vivo by bioluminescence imaging. After 11 days fLuc_P14 CD8 T cells had accumulated in the neoantigen expressing tumours, but not in the non-neoantigen expressing tumours. This was a critical experiment as it shows that the KP cells in the poised state do not have leaky expression in this transplant model and therefore do not stimulate an immune response.

The authors subsequently looked for leaky neoantigen expression in a GEMM containing the NINJA targeting complex at the ROSA26 site (a commonly used site in GEMMs for constitutive gene expression in mice). GFP+ peripheral blood mononuclear cells (PBMCs) were examined to assess leakiness. Leakiness would make the immune system tolerized to the neoantigen construct.

NINJA mice crossed with FLPo Tg mice, which would constitutively activate the expression of the neoantigen construct had PBMCs that were all GFP+. NINJA mice alone had no GFP+ PBMCs, but NINJA mice crossed with Cre Tg mice, which would put the regulatory module into a poised state, had less than 1% positive GFP PBMCs.

To more rigorously test the system, the authors infect NINJA mice crossed with transgenic mice containing CD8 and CD4 T cell receptors specific for the lymphocytic choriomeningitis virus (LCMV). T Cell responses in this system were indistinguishable from responses in control B6 mice suggesting NINJA mice are not centrally tolerized.

The authors then go on to test out the regulatory module in vivo. To do this the mice were infected in the footpad with Ad-Cre-recombinase and treated with doxycycline/tamoxifen (the three levels of regulation mentioned in Figure 1a). Robust CD8 and CD4 T cell responses were observed only in mice treated with doxycycline/tamoxifen. This essentially demonstrates that their system works, as this GEMM is the full novel model the authors aimed to make.

Finally, the authors temporally separate tumour induction and neoantigen expression. Delayed doxycycline/tamoxifen exposure 14 days after Ad-Cre administration resulted in similar CD8 and CD4 T cell responses to what was observed in mice treated with doxycycline/tamoxifen at the time of infection with Ad-Cre. The authors later mention that NINJA mice crossed with Cre Tg mice, which have the regulatory module in the poised state show some leakiness of the neoantigen.

 

What I liked about this work:

This model will be very important and useful to the field for understanding the immune response to tumour neoantigens and studying immunological tolerance.

Specific neoantigens could potentially be tested in this model, allowing scientists to observe differences in tumour immune response to different neoantigens.

This paper rigorously tests their novel NINJA system, clearly demonstrating its strengths and weaknesses.

In the cancer field, viable tumour immune models are missing. This mouse model could help fill that gap.

Open questions:

Q1: In this mouse model, both Adeno viral Cre-recombinase, doxycycline and tamoxifen are required to induce neoantigen expression. Do the authors observe higher toxicities in the mice that have to be exposed to all of these factors?

Q2: Although this novel mouse model is an exciting new model that will be important in the cancer field going forward, might it be difficult to model a clinically relevant immune response with only one neoantigen?

Q3: If NINJA-C express neoantigens in less than 1% of cells and this leads to complete central tolerance towards neoantigens, won’t this make a mouse tumour model where neoantigens are expressed after tumour initiation potentially difficult depending on the time of neoantigen expression? If for example the authors induced neoantigen expression several months after tumour initiation, would there be a robust CD8 and CD4 response?

1. DuPage, M. & Jacks, T. Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. Curr. Opin. Immunol. (2013).
2. Westcott, P. M. K. et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature Publishing Group 517, 489–492 (2015).
3. McFadden, D. G. et al. Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma. 113, E6409–E6417 (2016).
4. Chung, W.-J. et al. Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous. Proceedings of the National Academy of Sciences of the United States of America 201708391 (2017). doi:10.1073/pnas.1708391114
5. Schumacher, T. N., Scheper, W. & Kvistborg, P. Cancer Neoantigens. Annu. Rev. Immunol. 37, 173–200 (2019).
6. Dupage, M. et al. Endogenous T Cell Responses to Antigens Expressed in Lung Adenocarcinomas Delay Malignant Tumor Progression. 19, 72–85 (2011).

Tags: cancer, gemm, neoantigen

Posted on: 4 March 2020

doi: https://doi.org/10.1242/prelights.17425

Read preprint (No Ratings Yet)